Withdrawn study: could hydroxychloroquine help High-Risk pregnancies?

NCT ID NCT04275778

Terminated Disease control Sponsor: Assistance Publique - Hôpitaux de Paris Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study was designed to see if adding hydroxychloroquine to standard treatment (aspirin and heparin) could help women with antiphospholipid syndrome have a healthy full-term pregnancy. It planned to enroll pregnant women before 14 weeks of gestation. However, the trial was withdrawn before any participants were enrolled, so no conclusions can be drawn.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: hydroxychloroquine
What this could lead to: If it had succeeded, this could have pointed toward a way to improve the chance of a healthy full-term pregnancy for women with antiphospholipid syndrome.
What could go wrong: The trial was withdrawn before enrolling anyone, so no results are available. Even if conducted, the benefit of adding hydroxychloroquine was uncertain and the study was small.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ANTICOAGULANTS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

antiphospholipid syndrome primary antiphospholipid syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ANTICOAGULANTS ANTIPHOSPHOLIPID SYNDROME IN PREGNANCY

Contacts and locations

Locations

Hopital Saint Antoine

Paris, 75012, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.